Related Experiment Video
Updated: Oct 11, 2025
Author Spotlight: Patient-Informed 3D Model for Studying Glioblastoma Invasion via Interstitial Fluid Flow
Published on: October 18, 2024
Bringing vascularization into glioblastoma in vitro models
Catarina Pacheco1, Fátima Baltazar2, Bruno M Costa2
1i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-393 Porto, Portugal; INEB - Instituto Nacional de Engenharia Biomédica, Universidade do Porto, Rua Alfredo Allen 208, 4200-393 Porto, Portugal; CESPU - Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Rua Central de Gandra 1317, 4585-116 Gandra, Portugal.
Tissue engineering advances enable the creation of in vitro glioblastoma models that better mimic tumor biology. These models improve drug screening and therapy development for glioblastoma (GBM).
Area of Science:
- Biomedical Engineering
- Oncology
- Drug Discovery
Background:
- Tumor blood vessels are crucial for glioblastoma (GBM) growth and resistance to therapy.
- Conventional in vitro GBM models inadequately represent tumor biology, limiting their clinical applicability.
- There is a need for more representative preclinical models to advance GBM research.
Purpose of the Study:
- To explore the integration of tissue engineering techniques for developing advanced in vitro GBM models.
- To assess the potential of these enhanced models in improving GBM preclinical research and drug development.
Main Methods:
- Utilizing tissue engineering to incorporate tumor vasculature into in vitro GBM models.
- Comparing the biological relevance of new engineered models with conventional GBM models.
Main Results:
- Engineered in vitro models provide a more accurate representation of glioblastoma tumor biology, including vascularization.
- These advanced models offer improved conditions for studying GBM growth and therapy resistance compared to conventional models.
Conclusions:
- Tissue-engineered in vitro models represent a significant advancement for preclinical glioblastoma research.
- These models can enhance high-throughput drug screening and facilitate the clinical translation of novel GBM therapies.
